Publications by authors named "Delphine Schampers"
Article Synopsis
- Recent changes in treating desmoid-type fibromatosis (DF) favor "watchful waiting" over surgery, with systemic therapies like sorafenib recommended for progressive cases.
- A study at Ghent University Hospital reviewed 11 DF patients treated with sorafenib, revealing a median treatment duration of 20.4 months and varying outcomes: 36.4% had partial responses, while 54.5% experienced stable disease.
- Most patients (81.8%) faced notable toxicity, particularly skin issues, and many required dose adjustments, highlighting that while sorafenib is effective, careful monitoring for side effects is crucial.
